Research Topics
| Anna Suk Fong LokSummaryAffiliation: University of Michigan Country: USA Publications
| Collaborators
|
Detail Information
Publications
Evolution of nucleoside/tide analogues for hepatitis B: is the ideal drug here yet?Anna S F Lok
Division of Gastroenterology, University of Michigan Health System, 3912 Taubman Center, SPC 5362, Ann Arbor, MI 48109, USA
J Hepatol 51:416-8. 2009
Preliminary study of two antiviral agents for hepatitis C genotype 1Anna S Lok
Department of Internal Medicine, Division of Gastroenterology, 3912 Taubman Center, SPC 5362, University of Michigan Medical Center, Ann Arbor, MI 48109, USA
N Engl J Med 366:216-24. 2012..Patients with chronic hepatitis C virus (HCV) infection who have not had a response to therapy with peginterferon and ribavirin may benefit from the addition of multiple direct-acting antiviral agents to their treatment regimen...
Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trialAnna S Lok
Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI 48109, USA
Hepatology 49:1828-37. 2009..Decreased alcohol intake and improved metabolic parameters are associated with a decline in steatosis and may modulate hepatitis C progression...- Does antiviral therapy for hepatitis B and C prevent hepatocellular carcinoma?Anna Suk Fong Lok
University of Michigan, Ann Arbor, Michigan 48109, USA
J Gastroenterol Hepatol 26:221-7. 2011..Safer, more effective, and more affordable antiviral therapies are needed for both hepatitis B and hepatitis C so more patients can benefit from treatment and more HCCs can be prevented... - Long-term safety of lamivudine treatment in patients with chronic hepatitis BAnna S F Lok
Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, 48109 0362, USA
Gastroenterology 125:1714-22. 2003..The aim of this analysis was to determine the incidence of hepatitis flares, hepatic decompensation, and liver-disease-related (LDR) serious adverse events (SAE) during long-term lamivudine treatment... - How to diagnose and treat hepatitis B virus antiviral drug resistance in the liver transplant settingAnna S F Lok
Division of Gastroenterology, University of Michigan Hospitals, Ann Arbor, Michigan 48109, USA
Liver Transpl 14:S8-S14. 2008..Occurrence of antiviral drug resistance can be reduced by the use of the most potent nucleos(t)ide analogue(s) with the highest genetic barrier to resistance, emphasis of medication compliance, and close monitoring of virologic response... - Outcome of sustained virological responders with histologically advanced chronic hepatitis CTimothy R Morgan
Division of Gastroenterology, University of California Irvine, Irvine, CA, USA
Hepatology 52:833-44. 2010..CONCLUSION: Patients with advanced chronic hepatitis C who achieved SVR had a marked reduction in death/liver transplantation, and in liver-related morbidity/mortality, although they remain at risk for HCC... - Outcomes of patients with hepatitis B who developed antiviral resistance while on the liver transplant waiting listMelissa K Osborn
University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA
Clin Gastroenterol Hepatol 5:1454-61. 2007..Use of antiviral salvage therapy might decrease this risk... - Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensationScott K Fung
Division of Gastroenterology, University of Michigan, Medical Center, 3912 Taubman Center, Ann Arbor, MI 48109-0362, USA
J Hepatol 43:937-43. 2005..CONCLUSIONS: In conclusion, adefovir resistance can be associated with significant viral rebound and hepatic decompensation which may be fatal... - Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutationsJessica Tan
Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI 48109 0362, USA
J Hepatol 48:391-8. 2008..We sought to identify mutations associated with treatment failure to adefovir (ADV) and to determine virologic response to tenofovir (TDF) alone and in combination with emtricitabine (FTC) in these patients... - Changes in mood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis CRobert J Fontana
Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan, USA
Am J Gastroenterol 103:2766-75. 2008..The aim of this study was to identify baseline and on-treatment predictors of depression in CHC patients receiving peginterferon and ribavirin... - Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapyStephen N Wong
Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109 0362, USA
Liver Transpl 13:374-81. 2007..Maintenance therapy with NA after discontinuation of long-term HBIG therapy is associated with a low risk of HBV recurrence after OLT in compliant HBV patients... - Treatment of chronic hepatitis B: who to treat, what to use, and for how long?Scott K Fung
Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan 48109 0362, USA
Clin Gastroenterol Hepatol 2:839-48. 2004..Duration of treatment is at least 1 year with lamivudine and adefovir; longer duration of treatment is needed in most patients, but the optimal duration of treatment and the criteria for stopping treatment have not been established... - Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovirMunira Hussain
Division of Gastroenterology, University of Michigan Medical Center, 1500 East Medical Center Drive, 3912 Taubman Center, Box 0362, Ann Arbor, Michigan 48109-0362, USA
J Clin Microbiol 44:1094-7. 2006..Our study confirms that this assay can simultaneously detect the presence of lamivudine and adefovir resistance mutations in clinical samples, has a high degree of concordance with sequencing, and can detect mutants earlier... - Virologic response and resistance to adefovir in patients with chronic hepatitis BScott K Fung
Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109-0362, USA
J Hepatol 44:283-90. 2006..The cumulative probability of adefovir resistance at 2 years was 22%. Our data suggest that combination of lamivudine and adefovir may prevent emergence of adefovir resistance in patients with lamivudine-resistant HBV... - Comparison of clinical outcomes in chronic hepatitis B liver transplant candidates with and without hepatocellular carcinomaStephen N Wong
Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109 0362, USA
Liver Transpl 13:334-42. 2007..In conclusion, despite more advanced liver disease and a lower rate of transplantation, ITT survival of patients listed for HBV-cirrhosis was comparable to those with HBV-HCC, possibly related to beneficial effects of antiviral therapy... - Emotional distress during interferon-alpha-2B and ribavirin treatment of chronic hepatitis CRobert J Fontana
Department of Internal Medicine and the Consortium for Health Outcomes Innovation and Cost Effectiveness Studies, University of Michigan Medical School, Ann Arbor, MI 48109 0362, USA
Psychosomatics 43:378-85. 2002..Because of its brevity and simplicity, the Brief Symptom Inventory may prove to be a useful adjunct to clinician assessment in detecting and monitoring emotional distress during interferon-alpha treatment of chronic hepatitis C... - Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantationNorah A Terrault
Department of Medicine, Division of Gastroenterology, University of California at San Francisco, San Francisco, CA, USA
Liver Transpl 13:122-9. 2007..Important predictors of graft loss in HCV-infected patients were limited LDLT experience, pretransplant HCC, and higher MELD at transplantation... - Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis BRobert J Fontana
Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, USA
Liver Transpl 8:433-9. 2002.... - Effectiveness of interferon alpha-2b and ribavirin combination therapy in the treatment of naive chronic hepatitis C patients in clinical practiceThomas M Shehab
Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, USA
Clin Gastroenterol Hepatol 2:425-31. 2004..In addition, our data show that medication adherence is an important predictor of SVR in an academic clinical practice... - Re-weighting the model for end-stage liver disease score componentsPratima Sharma
Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, USA
Gastroenterology 135:1575-81. 2008..We re-estimated MELD coefficients and evaluated the effect of updated MELD on the liver transplant waiting list ranking... - HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype CChun Tao Wai
Division of Gastroenterology, University of Michigan, Ann Arbor, MI, USA
Hepatology 36:1425-30. 2002..Stratification for HBV genotypes should be considered in future clinical trials of antiviral therapy of chronic hepatitis B... - Antiviral therapy for chronic hepatitis BSyed Mohammed R Jafri
University of Michigan Health System, Ann Arbor, 48109, USA
Clin Liver Dis 14:425-38. 2010..These therapies are effective in suppressing HBV replication and have also been shown to prevent disease progression... - Impact of the model for end-stage liver disease allocation policy on the use of high-risk organs for liver transplantationMichael L Volk
Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan 48109, USA
Gastroenterology 135:1568-74. 2008..We aimed to determine whether implementation of MELD affected the quality of organs transplanted, the type of patients who receive the higher-risk organs, and the impact of these changes on their posttransplant survival... - Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosisRobert J Fontana
Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan 48109 0362, USA
Clin Gastroenterol Hepatol 7:219-26. 2009..Serum fibrosis marker levels during the lead-in treatment phase of patients enrolled in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) trial were determined... - Chronic hepatitis BAnna S F Lok
Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Box 0362, Ann Arbor, MI 48109-0362, USA
Hepatology 45:507-39. 2007 - Cognitive reserve and neuropsychological functioning in patients infected with hepatitis CLinas A Bieliauskas
Neuropsychology Section, Department of Psychiatry, University of Michigan Medical Center, Ann Arbor, Michigan 48105, USA
J Int Neuropsychol Soc 13:687-92. 2007..It is important to account for CRS when assessing cognitive findings in large-scale clinical trials... - Public health impact of antiviral therapy for hepatitis C in the United StatesMichael L Volk
Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI 48109, USA
Hepatology 50:1750-5. 2009..CONCLUSION: Efforts to improve rates of diagnosis and treatment will be required if the future public health burden of hepatitis C is to be ameliorated... - Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohortAnna S F Lok
Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Ann Arbor, MI 48210, USA
Hepatology 42:282-92. 2005..In conclusion, a model based on standard laboratory test results can be used to predict histological cirrhosis with a high degree of accuracy in 50% of patients with CHC... - Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trialAnna S F Lok
Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan 48109 0362, USA
Clin Gastroenterol Hepatol 5:245-54. 2007.... - Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assayAnna S F Lok
Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI 48109, USA
J Clin Microbiol 40:3729-34. 2002.... - Prevention of recurrent hepatitis B post-liver transplantationAnna S F Lok
University of Michigan, Ann Arbor, MI, USA
Liver Transpl 8:S67-73. 2002..6. Lamivudine resistance before LT is associated with an increased risk for recurrent hepatitis B post-LT. 7. A cost-effective prophylactic regimen to prevent recurrent hepatitis B should be tailored according to risk... - Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis CRobert J Fontana
Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109 0362, USA
Hepatology 45:1154-63. 2007.... - Chronic hepatitis BAnna S F Lok
University of Michigan, Ann Arbor, MI 48109, USA
N Engl J Med 346:1682-3. 2002 - Emotional distress in chronic hepatitis C patients not receiving antiviral therapyRobert J Fontana
Department of Internal Medicine, Division of Gastroenterology, University of Michigan Medical School, 3912 Taubman Center, Ann Arbor, MI 48109 0362, USA
J Hepatol 36:401-7. 2002..The aim of our study was to determine the prevalence, type, and severity of emotional distress in a large group of consecutive chronic hepatitis C (CHC) patients not receiving anti-viral therapy... - High-dose interferon alfa-2b and ribavirin in patients previously treated with interferon: results of a prospective, randomized, controlled trialRobert J Fontana
Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA
J Clin Gastroenterol 34:177-82. 2002..Kinetic studies have demonstrated a more rapid reduction in hepatitis C virus (HCV) RNA levels among patients taking high daily doses of interferon compared with those taking standard-dose interferon... - Chronic hepatitis B: update of recommendationsAnna S F Lok
Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Ann Arbor, MI 48109-0362, USA
Hepatology 39:857-61. 2004 - Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis CRobert J Fontana
Department of Internal Medicine, University of Michigan, 3912 Taubman Center, Ann Arbor, Michigan, USA
Gut 59:1401-9. 2010..The aim of this study was to explore the association of serum fibrosis marker levels with the risk of clinical and histological disease progression in a large cohort of patients with chronic hepatitis C (CHC)... - Prevention of hepatitis B virus-related hepatocellular carcinomaAnna S F Lok
of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Ann Arbor, MI 48109 0362, USA
Gastroenterology 127:S303-9. 2004..In addition, questions on who to treat and how long treatment should be administered must be addressed before recommendations on the use of antiviral therapy to prevent HBV-related HCC can be made... - Newer markers for hepatocellular carcinomaJorge A Marrero
Division of Gastroenterology, University of Michigan, 3912 Taubman Center, Ann Arbor, Michigan 48109 0362, USA
Gastroenterology 127:S113-9. 2004..There is an urgent need for novel biomarkers for the detection of early HCC; the National Cancer Institute proposal provides a framework for future validation studies... - Management of hepatitis B patients with antiviral resistanceScott K Fung
Division of Gastroenterology, University of Michigan, Ann Arbor, Mich, USA
Antivir Ther 9:1013-26. 2004..The ideal approach is to prevent antiviral resistance through judicious use of antiviral therapy and the use of more potent antiviral agents, possibly in combination... - Treatment of hepatitis BChun Tao Wai
Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Box 0362, Ann Arbor, MI 48109-0362, USA
J Gastroenterol 37:771-8. 2002..This review updates safety and efficacy data of interferon alpha and lamivudine in the treatment of chronic hepatitis B. Management strategies in different clinical scenarios and future treatments are also discussed... - Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infectionChi-Jen Chu
Department of Medicine, Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI, USA
Hepatology 36:1408-15. 2002..Given the fluctuating course of HBeAg-negative chronic hepatitis, it is not possible to define a single cutoff HBV DNA value for differentiating inactive carriers from patients with HBeAg-negative chronic hepatitis... - Presence of intrahepatic (total and ccc) HBV DNA is not predictive of HBV recurrence after liver transplantationMunira Hussain
Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI 48109 0362, USA
Liver Transpl 13:1137-44. 2007..Our findings suggest that occult HBV reinfection occurs in most HBV patients after OLT and continued administration of appropriate prophylactic therapy is important in preventing overt HBV recurrence... - Update on viral hepatitis in 2004Scott K Fung
Division of Gastroenterology, University of Michigan, Ann Arbor, 48109, USA
Curr Opin Gastroenterol 21:300-7. 2005..In addition, impressive gains were made in the treatment of hepatitis C virus infection in difficult-to-treat patients, including African Americans and those with HIV-hepatitis C virus coinfection... - Natural history of hepatitis B and outcomes after liver transplantationMary Ann Huang
Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical Center, 3912 Taubman Center, Ann Arbor, MI 48109, USA
Clin Liver Dis 7:521-36. 2003.... - Hepatitis B virus variantsWatcharasak Chotiyaputta
Division of Gastroenterology, University of Michigan Health System, Ann Arbor, MI, USA
Nat Rev Gastroenterol Hepatol 6:453-62. 2009.... - Update on viral hepatitis: 2005Stephen N Wong
Division of Gastroenterology, University of Michigan Medical School, Ann Arbor, 48109, USA
Curr Opin Gastroenterol 22:241-7. 2006..Advances have been made in hepatitis C treatment including patients with genotypes 2 or 3 infection and decompensated cirrhosis... - Beyond utilitarianism: a method for analyzing competing ethical principles in a decision analysis of liver transplantationMichael L Volk
Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan 48109, USA
Med Decis Making 28:763-72. 2008..In this study, the authors examine a method to incorporate competing ethical principles in a decision analysis of liver transplantation for a patient with acute liver failure (ALF)... - Management of patients with hepatitis B virus-induced cirrhosisScott K Fung
Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Ann Arbor, MI 48109-0362, USA
J Hepatol 42:S54-64. 2005 - Noninvasive monitoring of patients with chronic hepatitis CRobert J Fontana
Division of Gastroenterology, University of Michigan Health System, Ann Arbor, MI, USA
Hepatology 36:S57-64. 2002..There is an urgent need to develop and validate noninvasive tests that can accurately reflect the full spectrum of hepatic inflammation and fibrosis in chronic hepatitis C... - Drug insight: Nucleoside and nucleotide analog inhibitors for hepatitis BScott K Fung
Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI 48109-0362, USA
Nat Clin Pract Gastroenterol Hepatol 1:90-7. 2004..Several other nucleoside and nucleotide analogs are being evaluated in phase II/III clinical trials for hepatitis B... - Indications for therapy in hepatitis BBulent Degertekin
Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109, USA
Hepatology 49:S129-37. 2009..All patients who are not initiated on treatment should continue to be monitored so treatment can be started if and when the indication arises... - Evolution of multi-drug resistant hepatitis B virus during sequential therapyHyung Joon Yim
Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109-0362, USA
Hepatology 44:703-12. 2006..De novo combination therapy may prevent the emergence of multi-drug resistant mutants... - Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype CChi-Jen Chu
Division of Gastroenterology, Department of Medicine, University of Michigan and VA Medical Center, Ann Arbor, Michigan, USA
Gastroenterology 122:1756-62. 2002..CONCLUSIONS: HBV genotype B is associated with earlier HBeAg seroconversion than genotype C. This finding may explain the less active/progressive liver disease in patients with genotype B... - Hepatitis B: progress in the last decadeAnna S F Lok
Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Ann Arbor, USA
Semin Liver Dis 23:1-4. 2003 - Identification and management of hepatitis C patients in primary care clinicsThomas M Shehab
Division of Gastroenterology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, Michigan 48109, USA
Am J Gastroenterol 98:639-44. 2003..Interventions should be developed to optimize early diagnosis of hepatitis C as significant liver disease may be present despite the absence of symptoms... - Hepatitis B virus genotypes in the United States: results of a nationwide studyChi-Jen Chu
Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Box 0362, Ann Arbor, Michigan 48109-0362, USA
Gastroenterology 125:444-51. 2003..HBV genotypes may account for the heterogeneity in disease manifestations among patients with chronic HBV infection... - Rapid and sensitive assays for determination of hepatitis B virus (HBV) genotypes and detection of HBV precore and core promoter variantsMunira Hussain
Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan 48109-0362, USA
J Clin Microbiol 41:3699-705. 2003..INNO-LiPA is rapid, sensitive, and reliable-thus enabling accurate determination of HBV genotypes and detection of PC and CP variants in a large population of patients... - Prevalence of HBV precore/core promoter variants in the United StatesChi-Jen Chu
Division of Gastroenterology, University of Michigan, Ann Arbor, MI, USA
Hepatology 38:619-28. 2003..Physicians should be aware of the existence of HBV precore and core promoter variants and the clinical condition of "HBeAg-negative chronic hepatitis.".. - A genotype-independent real-time PCR assay for quantification of hepatitis B virus DNAYing Liu
Division of Gastroenterology, University of Michigan Medical Center, 1500 East Medical Center Dr, 3912 Taubman Center, Box 0362, Ann Arbor, MI 48109 0362, USA
J Clin Microbiol 45:553-8. 2007..We have established a real-time PCR assay that is genotype independent and can accurately quantify a wide range of HBV DNA levels. Further studies of additional samples are ongoing to validate the genotype independence of our assay... - Update on viral hepatitis: 2008Bulent Degertekin
Division of Gastroenterology, University of Michigan Health System, Ann Arbor, Michigan 48109, USA
Curr Opin Gastroenterol 25:180-5. 2009..The present review is a concise review of recent developments in the field of viral hepatitis, based on publications between December 2007 and November 2008... - Combination of HBIG and lamivudine-resistant mutations: a formula for trouble?Robert J Fontana
Division of Gastroenterology University of Michigan Medical School Ann Arbor, MI, USA
Liver Transpl 8:1082-4. 2002 - Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis CChihiro Morishima
Department of Laboratory Medicine, Virology Division, University of Washington, Seattle, WA, USA
Hepatology 48:1412-9. 2008..However, because patients with positive TMA results may achieve SVR, management decisions during therapy should not be based on a single positive TMA test result... - Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis CKirti Shetty
Division of Transplantation, Georgetown University Hospital, Washington, DC 20007, USA
Liver Transpl 14:534-40. 2008..Occult HBV infection is strongly associated with the presence of anti-HBc, history of injection drug use, and explant-proven HCC... - Occult hepatitis B virus infection in patients with hepatocellular carcinoma: Innocent bystander, cofactor, or culprit?Jorge A Marrero
Gastroenterology 126:347-50. 2004 - Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C TrialAdrian M Di Bisceglie
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Saint Louis University School of Medicine, 3635 Vista Avenue, St Louis, MO 63110, USA
J Hepatol 43:434-41. 2005..We assessed serum AFP among patients with chronic hepatitis C and advanced fibrosis to establish predictors of AFP elevations and changes with antiviral therapy... - Treatment of hepatitis B: who, when, and how?Stephen N Wong
Arch Intern Med 166:9-12. 2006 - Antiviral options for the treatment of chronic hepatitis BMelissa K Osborn
Division of Infectious Diseases, Emory University School of Medicine Atlanta, GA, USA
J Antimicrob Chemother 57:1030-4. 2006..Development of drug resistance is a major concern with long-term treatment. Even with successful therapy, patients remain at risk for reactivation of viral replication and require lifelong monitoring... - Tenofovir disoproxil fumarate: role in hepatitis B treatmentStephen N Wong
Hepatology 44:309-13. 2006 - HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trialChihiro Morishima
Department of Laboratory Medicine, University of Washington, Seattle, WA 98104, USA
Hepatology 44:360-7. 2006..In patients with negative PCR results during treatment, a single positive TMA test did not exclude SVR, although persistently positive tests did... - Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic statusAdrian M Di Bisceglie
Department of Internal Medicine, Saint Louis University School of Medicine, St. Louis, Missouri 63110, USA
Am J Gastroenterol 98:2060-3. 2003..These preliminary findings indicate the need for a more detailed study of ethnic variability in the pathogenesis of HCC... - Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trialGregory T Everson
Section of Hepatology, Division of Gastroenterology and Hepatology, University of Colorado School of Medicine, Denver, CO, USA
Hepatology 44:1675-84. 2006..In conclusion, disease severity is a major independent determinant of rate of SVR in patients with advanced chronic hepatitis C. New strategies are needed to optimize antiviral therapy in these "difficult-to-cure" patients... - Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis CMitchell L Shiffman
Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA 23298, USA
Gastroenterology 132:103-12. 2007..However, prior studies did not assess the impact of reducing the dose of peginterferon independent of ribavirin or differentiate between dose reduction or interrupting or prematurely discontinuing treatment... - Liver transplantation for patients with lamivudine-resistant HBV: what is the optimal prophylactic strategy?Anna S F Lok
Liver Transpl 11:490-3. 2005 - Antiviral therapy for pre- and post-liver transplantation patients with hepatitis BJessica Tan
Liver Transpl 13:323-6. 2007 - Management of hepatitis B: summary of a clinical research workshopJay H Hoofnagle
Liver Disease Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
Hepatology 45:1056-75. 2007..Clearly, many basic and clinical research challenges remain in defining optimal means of management of chronic hepatitis B... - Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) TrialLeonard B Seeff
Division of Digestive Diseases and Nutrition, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
Hepatology 47:605-12. 2008..Because its use among these HALT-C participants was self-motivated and uncontrolled, however, only a well-designed prospective study can determine whether silymarin provides benefit to persons with chronic hepatitis C... - Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis CKaren L Lindsay
Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA
Clin Gastroenterol Hepatol 6:234-41. 2008..Although viral kinetic profiles in treatment responders shed light on the mechanism of action of interferon and ribavirin, minimal information is available to explain why some patients experience little or no virologic suppression... - When to start and stop hepatitis B treatment: can one set of criteria apply to all patients regardless of age at infection?Bulent Degertekin
Ann Intern Med 147:62-4. 2007 - Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection?Scott K Fung
Hepatology 40:790-2. 2004 - Hepatitis B virus genotypes, precore and core promoter variants among predominantly Asian patients with chronic HBV infection in a Canadian centerScott K Fung
Department of Medicine, University of Toronto, Toronto, ON, Canada
Liver Int 26:796-804. 2006..Virological and clinical characteristics of these patients reflect their country of origin. Our findings highlight the need to monitor the changing patterns of HBV infection in countries with large immigrant populations...